A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study, in ...
(L to R) Justin Mattice, SVP and general manager at Envo, moderates a panel at Reuters Pharma USA with Kyowa Kirin's Debra Jennings, EVERSANA's Faruk Abdullah, Gilead Science's Pranay Butala, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback